Which Sleep Aids Are Safe for People Over 65?

For people over 65, the safest sleep aid is usually not the one with the gentlest-looking box. It is the one that has been screened for next-day steadiness, confusion, anticholinergic effects, interactions with the rest of the medication list, and whether the person can still get to the bathroom safely at 3 a.m.

The short answer is this: older adults should generally avoid common over-the-counter antihistamine sleep aids such as diphenhydramine and doxylamine, be cautious with benzodiazepines and Z-drugs, and consider safer paths such as CBT-I, low-dose melatonin, low-dose doxepin, ramelteon, or a dual orexin receptor antagonist when a clinician agrees the fit is right. The Cleveland Clinic Journal of Medicine review on insomnia in older adults reports that about 50% of older adults have difficulty starting or maintaining sleep, while 12% to 20% meet criteria for insomnia disorder.[1] CDC data also show that 15.8% of adults 65 and older use sleep aids most days or every day, including 8.8% using prescription sleep aids and 7.6% using over-the-counter sleep aids.[2]

That makes this a common decision, not a niche concern. It is also a decision where the brand name can distract from the active ingredient. Benadryl, ZzzQuil, Tylenol PM, Advil PM, and many “nighttime” formulas may contain diphenhydramine. Some Unisom products contain doxylamine. Those two ingredients are not interchangeable with safer sleep options just because they sit on the same pharmacy shelf.

A Safety Map for Sleep Aids After 65

The American Geriatrics Society Beers Criteria is useful here because it cuts through packaging language. Instead of asking whether a product is “strong,” “natural,” or “non-habit forming,” it asks whether a drug is potentially inappropriate for older adults because its risks often outweigh its benefits in this age group. Secondary summaries of the 2023 Beers Criteria identify diphenhydramine, doxylamine, benzodiazepines, and Z-drugs as medications of concern for many adults 65 and older.[1][3]

Why “PM” Antihistamines Are a Different Problem After 65

Diphenhydramine and doxylamine can make a person sleepy because they block histamine. The trouble is that they also have anticholinergic effects. In practical terms, that means they can interfere with acetylcholine, a chemical messenger involved in memory, attention, urination, bowel function, and other body systems. In an older adult, the result may not look like a dramatic drug reaction. It may look like waking up foggy, being unsteady in the hallway, getting constipated, having trouble emptying the bladder, or seeming “not quite right” the next morning.

This is where over-the-counter status becomes misleading. A product can be easy to buy and still be a poor fit for an aging nervous system. Mayo Clinic’s overview of OTC sleep aids notes that antihistamine sleep aids can cause next-day drowsiness, dizziness, confusion, constipation, dry mouth, and urinary retention, with older adults at greater risk of these effects.[4]

The cognitive-risk discussion needs care. A widely discussed study reported that people with three or more years of cumulative strong anticholinergic exposure had a 54% higher dementia risk than those with lower exposure, as summarized by Harvard Health.[5] That does not prove that one Benadryl tablet causes dementia, and it does not isolate diphenhydramine as the only possible culprit. It does make long-term, casual anticholinergic use harder to defend when safer insomnia treatments exist.

Falls are the more immediate worry in many homes. A Penn State report on older adults with insomnia described research linking prescription sleep medication use with greater fall risk in older adults.[6] A 2025 estimate also reported a 33% greater fall risk associated with sleep medication use, with a hazard ratio of 1.33 and a 95% confidence interval of 1.18 to 1.51. Even when a sleep aid works, the benefit has to be weighed against what happens when the person stands up half-awake in the dark.

Doxylamine deserves the same suspicion as diphenhydramine. It is often encountered through Unisom, but Unisom is a brand family rather than a single ingredient. Some products contain doxylamine; others may contain different active ingredients. If doxylamine is the one on the label, older adults should treat it as an anticholinergic sleep aid to avoid for routine use. A deeper ingredient-specific discussion is available in our guide to doxylamine as a sleep aid.

Prescription Sleep Medicines Are Not Automatically Safer

A prescription can be the right answer, but the prescription pad does not erase geriatric risk. Benzodiazepines and Z-drugs are the two groups that most often create false reassurance: one sounds familiar from decades of use, the other was marketed as a more targeted sleep medicine. In older adults, both can still leave a person sedated, slower to react, or confused enough for the night’s “help” to become the next morning’s injury.

Beers-focused insomnia guidance for older adults lists benzodiazepines and Z-drugs among medications that are potentially inappropriate for many people in this age group.[1] The issue is not that no older adult can ever receive one. It is that routine use for insomnia should require a specific reason, a dose chosen for age and frailty, a duration limit, and a plan to reassess. “It helped me sleep” is only half the outcome. The other half is whether the person was steady, oriented, and functioning the next day.

Population-level modeling gives a sense of why clinicians worry about these decisions. USC Schaeffer summarized a Lancet Healthy Longevity analysis estimating that avoiding sleep medications among 15.3 million Americans age 50 and older could reduce lifetime fall incidence by 8.5% and cognitive impairment by 2.1%, with projected savings of $101 billion.[7] Modeling is not the same as watching an individual patient improve after stopping a drug, but it points in the same direction geriatric clinicians see at the bedside: small medication decisions can accumulate into large harms.

The Better Starting Point for Chronic Insomnia: CBT-I

For chronic insomnia, cognitive behavioral therapy for insomnia, or CBT-I, is the first-line treatment recommended by major medical groups including the American Academy of Sleep Medicine, the American Geriatrics Society, and the American Academy of Family Physicians, as summarized in older-adult insomnia guidance.[1][8] That is not because clinicians are trying to deny medication to tired people. It is because CBT-I treats the sleep pattern without adding anticholinergic burden, sedative accumulation, or a new fall-risk variable to the medication list.

CBT-I is not just a collection of pleasant bedtime tips. It usually works with sleep scheduling, stimulus control, sleep restriction or compression, thoughts and behaviors around sleep, and relapse prevention. The CCJM review reports an effect size of 0.96 for CBT-I compared with 0.87 for pharmacotherapy, with CBT-I showing longer-lasting durability.[1] In plain language, it can work at least as well as medication for many people, and its benefits are less likely to disappear the moment a pill bottle is empty.

The problem is access. A person can be told CBT-I is first-line and still have no nearby therapist, no insurance coverage, no comfort with apps, or no energy to navigate a portal at midnight. Digital CBT-I and structured primary-care sleep programs may help close that gap, and the HABIT trial examined a behavioral sleep intervention delivered in primary care for older adults.[9] Still, the practical question for many families is not “CBT-I or medication forever.” It is “what can we start safely while we try to get the better long-term treatment in place?”

Lower-Risk OTC Options: Useful, but Not Magic

Melatonin

Melatonin is often a more reasonable OTC conversation than diphenhydramine or doxylamine, especially when the main issue is sleep timing. But the dose matters. Many older adults do better starting low, such as 0.5 to 1 mg, and avoiding routine escalation above 3 mg unless a clinician has a reason. More is not automatically more physiologic, and high-dose products can leave some people groggy or with vivid dreams.

The expected benefit is modest. A meta-analysis cited in the research brief found that melatonin in older adults reduced sleep latency by about 14 minutes and increased total sleep time by about 21 minutes. That can matter to someone who is exhausted, but it should not be sold as a guaranteed fix for years of insomnia.

The other concern is quality. In the United States, melatonin is sold as a dietary supplement, not regulated like a prescription drug. A Canadian study found melatonin content ranging from 83% below to 478% above the label claim, a finding discussed in the broader literature on melatonin supplement variability.[10] That is why it is worth choosing products carefully and avoiding the quiet dose creep that happens when one gummy becomes two, then three. Our review of home remedies for insomnia goes deeper into supplement-label and safety issues.

Magnesium glycinate and L-theanine

Magnesium glycinate and L-theanine are sometimes discussed as gentler options, and they may be reasonable to ask about. They should not be placed on the same evidence shelf as CBT-I, low-dose doxepin, ramelteon, or DORAs for older-adult insomnia. The older-adult-specific evidence is thinner, and supplements still matter on a medication list. Kidney disease, blood pressure medicines, sedatives, and other conditions can change whether a supplement is benign for a particular person.

Prescription Options That May Fit Better

Low-dose doxepin

Low-dose doxepin is one of the more useful examples of why dose and indication matter. At antidepressant-range doses, doxepin is a tricyclic antidepressant with anticholinergic concerns. At very low insomnia doses, commonly 1 to 3 mg in older-adult discussions, it behaves differently enough to be considered for sleep maintenance in selected patients.

The CCJM review describes a 12-week randomized controlled trial in older adults in which low-dose doxepin produced significant sleep-maintenance improvement without next-day cognitive issues.[1] That makes it worth discussing when the main problem is waking during the night rather than falling asleep. It still belongs in a clinician-mediated plan: check the full medication list, start with an age-appropriate dose, and decide in advance what “working” means.

Ramelteon

Ramelteon is a prescription medication that acts on melatonin receptors. It is not an antihistamine and does not work by anticholinergic sedation. It may be most relevant when the problem is sleep onset. For an older adult who is tempted to take diphenhydramine because they “just need something to fall asleep,” ramelteon is the sort of alternative worth asking about, particularly when supplement quality or self-dosing with melatonin has become messy.

Dual orexin receptor antagonists

Dual orexin receptor antagonists, or DORAs, include suvorexant, lemborexant, and daridorexant. They work by blocking orexin signaling, a wake-promoting system, rather than by broadly sedating the brain through older antihistamine or benzodiazepine-like pathways. That mechanism does not make them risk-free, but it makes them an important option in the older-adult sleep-aid conversation.

The CCJM review reports favorable benefit-harm profiles for DORAs, including a number needed to treat of 3 for lemborexant, 8 for suvorexant, and under 10 for daridorexant, with a number needed to harm of 78 for daridorexant.[1] Those figures are helpful because they move the discussion beyond “strong” or “weak.” They ask how many people are likely to benefit and how many may be harmed.

The real-world barrier is access. DORAs can be expensive, and prior authorization can turn a carefully chosen option into weeks of phone calls. For someone on Medicare or a fixed income, “ask about a DORA” may be medically sound and financially frustrating at the same time. A practical plan may need a preferred formulary option, a documented reason to avoid anticholinergics and Z-drugs, and a fallback if coverage is denied.

What to Ask Before Taking Any Sleep Aid

The safest question is not “What is the strongest thing I can take?” It is “What problem are we treating, and what risk are we adding?” Sleep onset insomnia, waking at 2 a.m., restless legs, untreated sleep apnea, pain, nocturia, depression, anxiety, alcohol use, and medication side effects do not all point to the same sleep aid.

• Is the active ingredient diphenhydramine or doxylamine? If yes, ask whether it should be avoided because of anticholinergic risk.
• Is this medicine flagged by the Beers Criteria for adults 65 and older?
• Will it increase fall risk, confusion, urinary retention, constipation, or next-day driving and balance problems?
• Is the main problem falling asleep, staying asleep, waking too early, or sleeping at the wrong time?
• What is the lowest reasonable dose, and when will we stop or reassess it?
• Could CBT-I, digital CBT-I, sleep restriction support, or a referral be started instead of relying on nightly medication?
• If the recommended option is expensive, is there a covered alternative or a prior authorization plan?

A pharmacist can often answer the first two questions faster than anyone else, especially when a product hides the active ingredient behind “PM,” “nighttime,” or “sleep” branding. A clinician should be involved when insomnia is chronic, when the person has fallen, when memory has changed, when other sedatives are already on the list, or when a prescription option is being considered.

A Grounded Rule for Older Adults

For sleep aids for older adults, start by screening against the Beers Criteria. Avoid routine use of anticholinergic OTC antihistamines such as diphenhydramine and doxylamine. Treat chronic insomnia behaviorally when possible. If medication is needed, choose the option, dose, duration, and monitoring plan deliberately, with next-day steadiness and cognition treated as part of the outcome.

References

1. Insomnia in older adults, Cleveland Clinic Journal of Medicine, 2025
2. Sleep Medication Use in Adults Aged 18 and Over: United States, 2020, CDC National Center for Health Statistics
3. Beers Criteria, Cleveland Clinic
4. Sleep aids: Understand options sold without a prescription, Mayo Clinic
5. Common anticholinergic drugs like Benadryl linked to increased dementia risk, Harvard Health Publishing, 2015
6. Older adults with insomnia may fall even more when on prescription sleep meds, Penn State
7. Sleep Drug Reduction in Older Adults Could Increase Longevity, USC Schaeffer Center
8. Insomnia: Pharmacologic Therapy, American Academy of Family Physicians, 2017
9. The clinical and cost-effectiveness of nurse-delivered sleep restriction therapy for insomnia in primary care: the HABIT randomized controlled trial, The Lancet, 2023
10. Melatonin for the treatment of primary sleep disorders, PMC